Fri Aug 1 23:54:33 SGT 2014  
    Sexual health genital warts, Singapore (SG)
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Sexual health genital warts, Singapore (SG) | HIV STD TESTING SINGAPORE™


Sexual health genital warts, Singapore (SG) | HIV STD TESTING SINGAPORE™ @singaporesexualhealth_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) screening/diagnosis, testing/check treatment/removal/cure, Singapore. Private and confidential service. Definitions, references, and latest news.


Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.


Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Sexual health genital warts, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.


Latest News

Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine
Thu, 31 Jul 2014 04:00:00 +0100 | EurekAlert! - Cancer
(Landes Bioscience) A long-term follow-up study shows the sustained efficacy, immunogenicity and safety of GlaxoSmithKline's human papillomavirus vaccine Cervarix. Women vaccinated with the vaccine were followed for more than nine years, and vaccine efficacy against incident infection was 100 percent. This is the longest follow-up report for a licensed human papillomavirus vaccine. (Source: EurekAlert! - Cancer)

Blood and saliva tests help predict return of HPV-linked oral cancers
Thu, 31 Jul 2014 04:00:00 +0100 | EurekAlert! - Cancer
(Johns Hopkins Medicine) Physicians at Johns Hopkins have developed blood and saliva tests that help accurately predict recurrences of HPV-linked oral cancers in a substantial number of patients. The tests screen for DNA fragments of the human papillomavirus shed from cancer cells lingering in the mouth or other parts of the body. A description of the development is published in the July 31 issue of JAMA Otolaryngology -- Head & Neck Surgery. (Source: EurekAlert! - Cancer)

HPV vaccination in women aged 27 to 45 years: What do general practitioners think?
Wed, 30 Jul 2014 00:00:00 +0100 | BMC Women's Health - Latest articles

Long‐term HPV type‐specific risks of high‐grade cervical intraepithelial lesions: A 14‐year follow‐up of a randomized primary HPV screening trial
Tue, 29 Jul 2014 00:00:00 +0100 | International Journal of Cancer
Quantitative knowledge of the long‐term human papillomavirus (HPV) type‐specific risks for high‐grade cervical intraepithelial neoplasias Grades 2 and 3 (CIN2 and CIN3) is useful for estimating the effect of elimination of specific HPV types and clinical benefits of screening for specific HPV types. We estimated HPV type‐specific risks for CIN2 and CIN3 using a randomized primary HPV screening trial followed up for 14.6 years using comprehensive, nationwide registers. Poisson regression estimated cumulative incidences, population attributable proportions (PAR) and incidence rate ratios (IRRs) of high‐grade lesions by baseline HPV type, with censoring at date of first CIN2/3 or last registered cytology. Multivariate analysis adjusted for coinfections. IRRs were highest during the ...

Bowen's carcinoma of the penis with sebaceous differentiation associated with human papillomavirus type 16
Mon, 28 Jul 2014 00:00:00 +0100 | International Journal of Dermatology
(Source: International Journal of Dermatology)

DNA Methylation at the Novel CpG Sites in the Promoter of MED15/PCQAP Gene as a Biomarker for Head and Neck Cancers.
Sun, 27 Jul 2014 08:40:02 +0100 | Biomarker Insights
Authors: Ovchinnikov DA, Wan Y, Coman WB, Pandit P, Cooper-White JJ, Herman JG, Punyadeera C

Localized juvenile spongiotic gingival hyperplasia featuring unusual p16INK4A labeling and negative human papillomavirus status by polymerase chain reaction
Sun, 27 Jul 2014 00:00:00 +0100 | Journal of Oral Pathology and Medicine
ConclusionsHuman papillomavirus does not participate in the pathogenesis of LJSGH. P16INK4A expression in the absence of detectable HPV DNA can likely be attributed to the intense inflammation associated with LJSGH. (Source: Journal of Oral Pathology and Medicine)

Sensitive multiplexed DNA detection using silica nanoparticles as the target capturing platform.
Sat, 26 Jul 2014 18:35:46 +0100 | Talanta
We present a simple and sensitive method for multiplexed DNA detection by simultaneously capturing two different DNA sequences with a same silica nanoparticle (NP) through a sandwich mode. This biobarcode assay method was demonstrated by using oligonucleotide sequences of 64 bases associated with human papillomavirus (HPV) 16 and 18 L1 genes as model systems. The nonfluorescent carboxyl-modified silica NPs were prepared using water-in-oil (W/O) microemulsion methods. Avidin was immobilized on the surface of the NPs by covalent binding to the carboxyl linkers. The binding capacity of the avidin-covered NPs for ligand biotin was quantified and the results show that about 8 avidin molecules are bound to one nanoparticle. The silica nano-platforms were prepared through the biotin-avidin intera...

EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus‐related cancer incidence by gender and anatomic site of infection
Sat, 26 Jul 2014 00:00:00 +0100 | International Journal of Cancer
Human papillomaviruses (HPVs) cause cancer at multiple anatomic sites in men and women, including cervical, oropharyngeal, anal, vulvar and vaginal cancers in women and oropharyngeal, anal and penile cancers in men. In this EUROGIN 2014 roadmap, differences in HPV‐related cancer and infection burden by gender and anatomic site are reviewed. The proportion of cancers attributable to HPV varies by anatomic site, with nearly 100% of cervical, 88% of anal and <50% of lower genital tract and oropharyngeal cancers attributable to HPV, depending on world region and prevalence of tobacco use. Often, mirroring cancer incidence rates, HPV prevalence and infection natural history varies by gender and anatomic site of infection. Oral HPV infection is rare and significantly differs by gender; yet,...

HPV prevalence and genotype distribution in a population-based split-sample study of well-screened women using CLART HPV2 Human Papillomavirus genotype microarray system
Sat, 26 Jul 2014 00:00:00 +0100 | BMC Infectious Diseases